Key Details
Thyrocare Technologies Limited's Board of Directors, at its meeting held on July 23, 2026, discussed and granted in-principle approval for evaluating the proposed demerger of Nueclear Healthcare Limited's (NHL) radiology business undertaking. NHL is a wholly owned subsidiary engaged in advanced cancer diagnostics and nuclear medicine, operating PET-CT and CT imaging centres, providing nuclear medicine diagnostic services, and manufacturing radiopharmaceuticals through medical cyclotron facilities.
Transaction Structure
The proposed restructuring may be executed through:
- Scheme of arrangement
- Slump sale
- Business transfer
- Any other appropriate structure or mode as evaluated
The demerger would transfer NHL's radiology business to outside the group (third parties).
Current Status and Next Steps
The proposal is currently at an in-principle evaluation stage. Detailed terms of the proposed transaction will be placed before NHL's Board of Directors at the appropriate time. Following this, necessary disclosures and filings will be made with stock exchanges and other regulatory/statutory authorities.
Meeting Details
The Board meeting commenced at 2:45 PM and concluded at 3:35 PM on July 23, 2026.
Additional Information
The disclosure has been made available on the company's website at https://investor.thyrocare.com.
Financial Impact
Financial impact not quantified in the disclosure. The announcement represents preliminary evaluation stage only.
#Tags: #Thyrocare #Demerger #SEBIDisclosure #RegulatoryCompliance #CorporateRestructuring #Neutral